A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy

被引：0
作者：
Nan Zhang
Hong Zheng
Yunong Gao
Tong Shu
Hongguo Wang
Yan Cai
机构：
[1] Peking University Cancer Hospital and Institute,Gynecology Department, Key Laboratory of Carcinogenesis and Translational Research
[2] Ministry of Education of People’s Republic of China,undefined
来源：
Journal of Ovarian Research | / 17卷
关键词：
PARP; Epithelial ovarian cancer; BRCA; Maintenance therapy; Subsequent therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy
    Zhang, Nan
    Zheng, Hong
    Gao, Yunong
    Shu, Tong
    Wang, Hongguo
    Cai, Yan
    JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
  • [2] Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer
    Uekusa, Ryosuke
    Yokoi, Akira
    Watanabe, Eri
    Yoshida, Kosuke
    Yoshihara, Masato
    Tamauchi, Satoshi
    Shimizu, Yusuke
    Ikeda, Yoshiki
    Yoshikawa, Nobuhisa
    Niimi, Kaoru
    Suzuki, Shiro
    Kajiyama, Hiroaki
    CANCER MEDICINE, 2024, 13 (07):
  • [3] Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
    Papa, Anselmo
    Caruso, Davide
    Strudel, Martina
    Tomao, Silverio
    Tomao, Federica
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [4] Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
    Anselmo Papa
    Davide Caruso
    Martina Strudel
    Silverio Tomao
    Federica Tomao
    Journal of Translational Medicine, 14
  • [5] Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer
    Kulkarni, Sanat
    Gajjar, Ketankumar
    Madhusudan, Srinivasan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [6] Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients
    Sivakumaran, Tharani
    Krasovitsky, Michael
    Freimund, Alison
    Lee, Yeh Chen
    Webber, Kate
    So, Jane
    Norris, Christie
    Friedlander, Michael
    Mileshkin, Linda
    Au-Yeung, George
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (07) : 906 - 912
  • [7] Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
    Hinchcliff, Emily
    Westin, Shannon Neville
    Dal Molin, Graziela
    LaFargue, Christopher J.
    Coleman, Robert L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (05) : 956 - 968
  • [8] An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group
    Shimada, Muneaki
    Yoshihara, Kosuke
    Tanigawa, Terumi
    Nomura, Hiroyuki
    Hamanishi, Junzo
    Fujiwara, Satoe
    Tanabe, Hiroshi
    Kajiyama, Hiroaki
    Mandai, Masaki
    Aoki, Daisuke
    Enomoto, Takayuki
    Okamoto, Aikou
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (03)
  • [9] Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know
    Della Corte, Luigi
    Foreste, Virginia
    Di Filippo, Claudia
    Giampaolino, Pierluigi
    Bifulco, Giuseppe
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (05) : 543 - 554
  • [10] Genetic Implications for Cancer Management: The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer
    Walsh, Christine
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2024, 67 (04) : 711 - 719
12345